US FDA approves first mRNA flu shot from Moderna
Jefferies analysts had forecast US$750 million in US sales of Moderna’s flu shot and combination COVID-19-flu vaccine by 2030.
- Center-left2
- Center1
- Public / State1
no rewrites detected — all voices distinct
Summary
The company has been counting on the flu vaccine and a future COVID-19-flu combination shot to replace some of the lost COVID-19 vaccine revenue and to prove the long-term commercial potential of its mRNA technology, which has met resistance from some US health officials. The company withdrew its application for the combo shot in 2025 after the agency sought additional evidence demonstrating the effectiveness of its flu component.
Cross-referenced from 3 sources.
Factual coreconfirmed by several independent voices
Insufficient core: not enough independent confirmations to retain a shared fact.
Reported detailssecondary facts, each attributed to its source
The company has been counting on the flu vaccine and a future COVID-19-flu combination shot to replace some of the lost COVID-19 vaccine revenue and to prove the long-term commercial potential of its mRNA technology, which has met resistance from some US health officials.
according to The Straits Times - WorldThe company withdrew its application for the combo shot in 2025 after the agency sought additional evidence demonstrating the effectiveness of its flu component.
according to The Straits Times - World
Disputedincompatible versions — to verify
No factual contradiction detected between sources.
Framing by sidesame fact, different words — loaded terms highlighted
No notable framing divergence.
Blind spotwhat one side keeps silent
No blind spot detected: every side covers the same facts.
